UroGen Pharma Ltd.
NASDAQThree firms lifted price targets on URGN after a strong earnings print on August 5. That catalyst is still reverberating across the lending market and options desk. Guggenheim, HC Wainwright, and TD Cowen all raised targets on August 5–6. HC Wainwright went furthest — lifting its target from $45 to $75. TD Cowen moved from $50 to $60. Guggenheim went…
URGN cost to borrow surges to 0.45% — up 165% in one week as short interest falls to 9.7% of float.
Snapshot as of 20 Sept 2026
Three firms lifted price targets on URGN after a strong earnings print on August 5. That catalyst is still reverberating across the lending market and options desk. Guggenheim, HC Wainwright, and TD Cowen all raised…
UroGen Pharma enters its August 10 earnings window with a notable shift in short positioning — bears have trimmed their exposure meaningfully this week, even as the stock consolidates near a month-long high. The short…
UroGen Pharma heads into August earnings with a striking divergence at its core — short sellers are barely moving despite a 40% rally that has pushed the stock near analyst targets. The most arresting feature of this…
UroGen Pharma heads into its June 22 earnings report with a stock that has lost nearly 10% on the week — yet short sellers have been quietly covering rather than pressing their bets. The week's central tension is that…
UroGen Pharma heads into its May 11 earnings report with short sellers pulling back even as the stock's structural bear case remains firmly intact. The most striking feature of the past month is the divergence between…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for URGN — free to start on ORTEX.
Sign up for free →Open URGN on ORTEX